MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40123-025-01270-4

Медицинская библиотека · Ophthalmology and therapy · 2025

One-Year Efficacy and Tolerance of Myofix Defocus Spectacles for Control of Myopia Progression.

Iribarren Rafael, Szeps Abel, Kotlik Carlos, de Tomas Martin, Martin Gabriel, Rozema Jos, Lanca Carla

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

To report the 1-year efficacy of Myofix Defocus spectacles, designed to control the progression of myopia in childhood.

METHODS

A total of 47 children with myopia aged 7-15 years were enrolled. Cycloplegic objective refraction (spherical equivalent refraction, SE) and axial length (AL) were measured at baseline, 6 months, and 12 months. Linear regression models were used to identify risk factors of 12-month changes in SE and AL. For comparison, two virtual control groups of children were included. Tolerance was assessed through a questionnaire at each follow-up visit.

RESULTS

Of the initial cohort, 11 participants were lost to follow-up after 6 months due to reasons unrelated to lens design (77.1% retention rate). Over 12 months, the mean SE change in all eyes was - 0.21 ± 0.30 D, and AL change was 0.19 ± 0.13 mm. Progression was significantly different in participants who reported good compared to poor compliance (p < 0.001). At the 12-month follow-up, participants with good compliance had a mean SE progression of - 0.12 ± 0.25 D and a mean AL change of 0.17 ± 0.11 mm. In virtual controls, the mean annual SE progression was - 0.47 ± 0.36 D, and AL change was 0.26 ± 0.17 mm (both p < 0.001). In compliant participants, Myofix Defocus lens demonstrated a 75% reduction in SE and 37% reduction in AL compared to virtual controls.

CONCLUSIONS

After 1 year, Myofix Defocus spectacles slowed myopia progression in children, demonstrating comparable efficacy to other defocus-incorporated spectacle designs. Greater compliance resulted in better treatment effect. Further long-term studies are warranted to confirm these findings.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT07092072. Registered retrospectively on July 29, 2025.

Для цитирования: Iribarren Rafael, Szeps Abel, Kotlik Carlos, de Tomas Martin, Martin Gabriel, Rozema Jos, Lanca Carla. One-Year Efficacy and Tolerance of Myofix Defocus Spectacles for Control of Myopia Progression.. Ophthalmology and therapy. 2025. DOI: 10.1007/s40123-025-01270-4.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.